Back to search

National and Kapodistrian University of Athens

Σύγκριση της επίδρασης της σιταγλιπτίνης και της μετφορμίνης στα επίπεδα των πεπτιδίων που ρυθμίζουν την όρεξη σε ασθενείς με διαβήτη τύπου 2

Abstract

dc:description

Objective: To investigate the effect of sitagliptin and metformin on the gut peptide levels and on the glucose and lipid profiles in patients with type 2 diabetes.Materials and methods: Thirty one patients with newly diagnosed type 2 diabetes participated in this study and were allocated to two groups. One group [mean age: 59.5 ± 10.5 years, BMI: 33.4 ± 6.1 kg/m²] was started on metformin (850 mg daily) and the other group [mean age: 58.1 ± 7.9 years, BMI: 31.8 ± 8.1 kg/m²] was started on sitagliptin (100 mg daily) for four weeks. Patients received a test meal of mixed content and caloric value of 697 Kcal after an overnight fast, at baseline and four weeks after the treatment. The levels of ghrelin, GLP-1, GIP, PYY, insulin and glucose were measured before the meal initiation and 30, 60, 90, 120, 180, 240, 300, 360 minutes post-prandially. Lipid levels were measured at fasting state and 2, 4 and 6 hours post-prandially.Results: There was a significant reduction of glycated haemoglobin in both study groups four weeks after treatment initiation. In the metformin group, fasting HDL-C was higher at week 4. In the sitagliptin group, fasting glucose levels were significantly lower while fasting PYY and GLP-1 levels were significantly higher four weeks after treatment initiation.In the metformin group, there was a trend for higher post-prandial levels of HDL-C and lower post-prandial levels of insulin at week 4. In the sitagliptin group, there was a trend for lower post-prandial glucose levels while the post-prandial levels of HDL-C and GLP-1 were significantly higher at week 4. The two study groups displayed statistically significant difference in the post-prandial levels of GLP-1 four weeks after treatment initiation. Conclusion: Both sitagliptin and metformin are equally effective on fasting and post-prandial glucose control since they exert similar effect on the values of glycated haemoglobin in patients with type 2 diabetes. The administration of sitagliptin results in lower fasting glucose levels and higher post-prandial levels of HDL-C as well as in higher levels of fasting PYY and both fasting and postprandial GLP-1 compared to the administration of metformin four weeks after the treatment initiation.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Alexiadou, Kleopatra
  • Αλεξιάδου, Κλεοπάτρα

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41995

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Alexiadou, Kleopatra; Αλεξιάδου, Κλεοπάτρα. Σύγκριση της επίδρασης της σιταγλιπτίνης και της μετφορμίνης στα επίπεδα των πεπτιδίων που ρυθμίζουν την όρεξη σε ασθενείς με διαβήτη τύπου 2. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/41995